Clinical Guidelines
Feature

Novel Therapies and Multidisciplinary Strategies in Metastatic Triple-Positive Breast Cancer

Share

  • 1

    Metastatic triple-positive breast cancer is biologically complex.

  • 2

    HER2+ status linked with aggressive disease and poorer prognosis.

  • 3

    Dual HER2 blockade is critical for effective treatment.

  • 4

    CDK4/6 inhibitors being considered for HER2-positive cases.

  • 5

    Management of treatment-related toxicities is essential for patient care.

  • 6

    Key clinical trials influencing current treatment standards.

  • 7

    Monitoring for specific adverse effects like cardiotoxicity and pulmonary issues.

Original Source(s)

Novel Therapies and Multidisciplinary Strategies in Metastatic Triple-Positive Breast Cancer

  • by Danielle Roman, PharmD, BCOP, Kaitlyn Reeder, PA-C

  • February 27, 2026

  • 8 min

Related Content

New Collaboration to Automate Cell Therapy Manufacturing with Robotics

Focus on scaling cell therapy manufacturing using GMP-ready end-to-end robotic biomanufacturing technology

  • February 12, 2026

  • 2 min
Overcoming the Challenges of AI Antibody Analysis

Cracking the molecular code

Three Dana-Farber Cancer Institute scientific leaders elected as Fellows of the American Association for Cancer Research (AACR) Academy Class of 2026

Dr. Alice Shaw, Dr. Kimberly Stegmaier and Dr. Matthew Vander Heiden have been elected as Fellows of the American Association for Cancer Research (AACR) Academy Class of 2026.

  • by

  • February 3, 2026

  • 3 min